



ACCEPT

Addiction & Co-morbid Conditions: Enhancing Prevention & Therapeutics

Webex link to join from PC, Mac, iOS or Android:

<https://uwmadison.webex.com/uwmadison/j.php?MTID=m6dfbe50f3c56cb4719e74b72b73ef9>

[16](#)

Join by phone: +1-415-655-0001

Meeting number/Access code: 120 276 9209

Password: 12345

For attendance, purposes please text the following code: **ZOHJUB** to **608-260-7097**

Session Date: Friday, January 19, 2024

Didactic Topic and Presenter:

One EM Group's Approach to Opiate Use Disorder

Julie Doniere, MD, MPH – Practice Manager

Retired ED Physician

USA Today "Woman of the Year 2022"

-
- 12:15 PM: Attendance text-in – Introductions
 - 12:25 PM: Case Presentation
 - Presenter: Collin Michels, MD - *Assistant Professor (CHS), BerbeeWalsh Department of Emergency Medicine, University of Wisconsin School of Medicine & Public Health, Chief of Emergency Medicine, William S. Middleton Memorial VA*
 - 1 PM: Didactic Presentation and Discussion
 - Presenter: Julie Doniere, MD, MPH
 - 1:15 PM End of Session

Funding for this service was made possible by 435200-G-18-11448-285932-880 from Wisconsin Department of Health Services. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government or the State of Wisconsin.

CONTINUING EDUCATION INFORMATION:

Accreditation Statement



In support of improving patient care, the University of Wisconsin–Madison ICEP is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Designation Statements

American Medical Association (AMA)

The University of Wisconsin–Madison ICEP designates this live activity for a maximum of 1 *AMA PRA Category 1 Credit™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Nurses Credentialing Center (ANCC)

The University of Wisconsin–Madison ICEP designates this live activity for a maximum of 1 ANCC contact hour.

Accreditation Council for Pharmacy Education (ACPE)

The University of Wisconsin–Madison ICEP designates this knowledge-based activity for a maximum of 1.0 hours or 0.1 CEUs of CPE credit. Credit can be earned by successfully completing the activity and the evaluation. Credit will be provided to NABP CPE Monitor within 60 days after the activity completion.

2023 Universal Activity Number (UAN): JA0000358-0000-23-025-L01-P; JA0000358-0000-23-025-L01-T

Continuing Education Units

The University of Wisconsin–Madison ICEP, as a member of the University Professional & Continuing Education Association (UPCEA), authorizes this program for 0.1 continuing education units (CEUs) or 1 hour.

Medication Access and Training Expansion Act (MATE)

This session is designed to meet the requirements outlined in the Medication Access and Training Expansion (MATE) Act. ([Click here](#) for more information.) Number of hours: 1



ECHO ACCEPT
Addiction & Co-morbid Conditions: Enhancing Prevention & Therapeutics
2022-2024

One EM Group's Approach to Opiate Use Disorder
1/19/24

Didactic Presenter: Julie Doniere, MD, MPH

Case Presenter: Collin Michels, MD

Provided by the University of Wisconsin–Madison Interprofessional Continuing Education Partnership (ICEP)

Intended Audience:

Nurses, Nurse Practitioners, Pharmacists, Physicians, Physician Assistants, Pharmacy Technicians, Psychologists, Social Workers, Patient/Caregivers, Students

Objectives:

As a result of this educational regularly scheduled series, learners as members of the healthcare team will be able to:

- ▶ Describe the 4-tiered emergency department approach to patients that struggle with opiate use
- ▶ Identify and assess patients that might benefit from MAT in the Emergency Department.
- ▶ Demonstrate how to induce a person on buprenorphine in the emergency department

Policy on Disclosure

It is the policy of the University of Wisconsin–Madison Interprofessional Continuing Education Partnership (ICEP) to identify, mitigate and disclose all relevant financial relationships with ineligible companies* held by the speakers/presenters, authors, planners, and other persons who may influence content of this accredited continuing education (CE). In addition, speakers, presenters and authors must disclose any planned discussion of unlabeled/unapproved uses of drugs or devices during their presentation. For this accredited continuing education activity, all relevant financial relationships have been mitigated and detailed disclosures are listed below.

** Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies.*

Name	Role	Financial Relationship Disclosures	Discussion of Unlabeled/Unapproved uses of drugs/devices in presentation?	COI completion date
Randall Brown	RSS Chair	Usona Institute (Grant / Contract), multi-disciplinary association for psychedelic studies (Grant / Contract)	Yes	1/30/2023
Nada Rashid	RSS Coordinator	No relevant financial relationships to disclose	No	1/31/2023
Kathleen Maher	RSS Coordinator	No relevant financial relationships to disclose	No	1/30/2023
Ritu Bhatnagar	Planner	No relevant financial relationships to disclose	Yes	1/29/2023
Paul Hutson	Planner	No relevant financial relationships to disclose	Yes	1/28/2023
Susan Mindock	Planner	No relevant financial relationships to disclose	No	1/31/2023
Sheila Weix	Planner	No relevant financial relationships to disclose	No	2/3/2023
Kellene Eagen	Planner	No relevant financial relationships to disclose	No	1/27/2023
Joseph Galey	Planner	No relevant financial relationships to disclose	Yes	1/27/2023
David Leinweber	Planner	No relevant financial relationships to disclose	No	4/13/2023
Julie Doniere	Presenter	No relevant financial relationships to disclose	No	1/11/2024

Collin Michels	Presenter	No relevant financial relationships to disclose	No	1/3/2024
----------------	-----------	---	----	----------

Accreditation Statement



In support of improving patient care, the University of Wisconsin–Madison ICEP is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Designation Statements

American Medical Association (AMA)

The University of Wisconsin–Madison ICEP designates this live activity for a maximum of 1 *AMA PRA Category 1 Credit*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Nurses Credentialing Center (ANCC)

The University of Wisconsin–Madison ICEP designates this live activity for a maximum of 1 ANCC contact hour.

Accreditation Council for Pharmacy Education (ACPE)

The University of Wisconsin–Madison ICEP designates this knowledge-based activity for a maximum of 1.0 hours or 0.1 CEUs of CPE credit. Credit can be earned by successfully completing the activity and the evaluation. Credit will be provided to NABP CPE Monitor within 60 days after the activity completion.

2023 Universal Activity Number (UAN): JA0000358-0000-23-025-L01-P; JA0000358-0000-23-025-L01-T

Continuing Education Units

The University of Wisconsin–Madison ICEP, as a member of the University Professional & Continuing Education Association (UPCEA), authorizes this program for 0.1 continuing education units (CEUs) or 1 hour.

Medication Access and Training Expansion Act (MATE)

This session is designed to meet the requirements outlined in the Medication Access and Training Expansion (MATE) Act. ([Click here](#) for more information.) Number of hours: 1



Case Presentation

Collin Michels, MD

Assistant Professor, BerbeeWalsh Department of Emergency Medicine
University of Wisconsin School of Medicine and Public Health

Funding for this service was made possible by 435200-G-18-11448-285932-880 from Wisconsin Department of Health Services. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government or the State of Wisconsin.



Accreditation Statement:

In support of improving patient care, the University of Wisconsin–Madison ICEP is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Designation Statements

American Medical Association (AMA)

The University of Wisconsin–Madison ICEP designates this live activity for a maximum of 1 *AMA PRA Category 1 Credit*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Nurses Credentialing Center (ANCC)

The University of Wisconsin–Madison ICEP designates this live activity for a maximum of 1 ANCC contact hour.

Accreditation Council for Pharmacy Education (ACPE)

The University of Wisconsin–Madison ICEP designates this knowledge-based activity for a maximum of 1.0 hours or 0.1 CEUs of CPE credit. Credit can be earned by successfully completing the activity and the evaluation. Credit will be provided to NABP CPE Monitor within 60 days after the activity completion.

2023 Universal Activity Number (UAN): JA0000358-0000-23-025-L01-P; JA0000358-0000-23-025-L01-T

Continuing Education Units

The University of Wisconsin–Madison ICEP, as a member of the University Professional & Continuing Education Association (UPCEA), authorizes this program for 0.1 continuing education units (CEUs) or 1 hour.

Medication Access and Training Expansion Act (MATE)

This session is designed to meet the requirements outlined in the Medication Access and Training Expansion (MATE) Act. ([Click here](#) for more information.) Number of hours : 1

[For this educational activity there are no reported conflicts of interest](#)

Case Introduction

- ▶ **One-liner:** 28 year old F with history of recurrent urinary tract infections and pyelonephritis who presents with severe flank pain as well as concerns for opioid withdrawal
- ▶ **Primary question for discussion:** Undertreatment of opioid withdrawal vs precipitated withdrawal in the emergency department.

Medical & Behavioral Health Diagnosis:

- Pyelonephritis
- Asthma
- Metatarsal fractures / Lis Franc injury
- Chronic headaches (child)

Current Medications:

- No prescription medications
- Oxycodone 30mg tablets – 10-12 every day
- Occasional fentanyl due to difficulty obtaining oxycodone

Substance Use

- ▶ History: alcohol use disorder, opioid use disorder
- ▶ Consequences of Substance Use:
 - Social/occupational/educational: nanny, childcare jobs
 - Physical (including evidence of tolerance/withdrawal):
- ▶ Past treatments: 1 reported stay at behavioral health center a few years ago'

Social History:

- Social Factors/History: Non smoker, frequent alcohol use,
- Education/Literacy: unknown
- Income source: Nanny, intermittent childcare jobs

Family History:

- Mother: Hypertension, hyperlipidemia
- Father: substance use disorder (no other details)

Patient strengths & protective factors:

- Desire to seek treatment
- New to area
- Intake appointment at MAT clinic set up prior to this ED visit

Risk factors:

- History of AUD and OUD
- New to area / back and forth with prior living location
- No established primary care in area
- Hx of recurrent infections – painful
- Fentanyl addiction

ED Course

- ▶ Presented with flank pain
- ▶ Given acetaminophen, oxycodone 10mg
- ▶ No initial COWS documented

Vital signs / Labs

- ▶ BP: 103/69, pulse 98, RR 22, SpO2 99% on RA

~~13.4
7.2 292
39~~

140	107	6	88
3.5	25	0.47	

- ▶ UA: neg LE, nitrites, wbc, some bacteria
- ▶ HCG: negative
- ▶ CT negative

ED Course

- ▶ Flank pain
- ▶ Given acetaminophen, oxycodone 10mg
- ▶ No initial cows documented
- ▶ Desire for MAT discussed
- ▶ Observed until COWS 8 → Bup 4mg/1mg
- ▶ 1 hour later COWS 14 → Bup 8mg/2mg, ondansetron, zyprexa
- ▶ 1 hour later COWS 11 → Bup 8mg/2mg

Patient Goals & Motivations for Treatment

- ▶ Establish primary care
- ▶ Start buprenorphine
- ▶ Treat acute pain

Proposed Diagnoses

- ▶ UTI, pyelonephritis, zoster, ureterolithiasis, spinal epidural abscess
- ▶ Opioid withdrawal

Discussion:

- ▶ Primary question: Does this presentation represent mild precipitated withdrawal vs undertreatment?


Discussion:

- ▶ Primary question: Does this presentation represent mild precipitated withdrawal vs undertreatment?
- ▶ Observed until COWS 8 → Bup 4 - 1mg
- ▶ 1 hour later COWS 14 → Bup 8 – 2mg, ondansetron, zyprexa
- ▶ 1 hour later COWS 11 → Bup 8 – 2mg
- ▶ Discharged


Discussion:

- ▶ Discharged on 8mg/2mg BID x2 weeks
- ▶ Follow up at clinic – doing well

ED Buprenorphine Initiation



ED Buprenorphine Initiation



DSM-5 Substance Use Disorder ("Addiction")

- ▶ Tolerance
 - ▶ Withdrawal
- } **Physical Dependence ≠ Use Disorder**
- ▶ Larger amts/longer periods than intended
 - ▶ Persistent desire/failed attempts to quit/control use
 - ▶ Much time obtaining/using/recovering
 - ▶ Important activities sacrificed
 - ▶ Continued use despite known adverse effects
 - ▶ Failure to fulfill major obligations
 - ▶ Recurrent hazardous use
 - ▶ Craving
 - ▶ Ongoing use despite interpersonal problems
- 2-3 = mild
4-5 = moderate
≥ 6 = severe


By initialing here ___cm__ you have acknowledged that Project ECHO case consultations do not create or otherwise establish a provider-patient relationship between any ECHO clinician and any patient whose case is being presented in a teleECHO clinic.



One EM Group's Approach to Opiate Use Disorder

Julie Doniere, MD, MPH

Funding for this service was made possible by 435200-G-18-11448-285932-880 from Wisconsin Department of Health Services. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government or the State of Wisconsin.



Accreditation Statement:

In support of improving patient care, the University of Wisconsin–Madison ICEP is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Designation Statements

American Medical Association (AMA)

The University of Wisconsin–Madison ICEP designates this live activity for a maximum of 1 *AMA PRA Category 1 Credit*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Nurses Credentialing Center (ANCC)

The University of Wisconsin–Madison ICEP designates this live activity for a maximum of 1 ANCC contact hour.

Accreditation Council for Pharmacy Education (ACPE)

The University of Wisconsin–Madison ICEP designates this knowledge-based activity for a maximum of 1.0 hours or 0.1 CEUs of CPE credit. Credit can be earned by successfully completing the activity and the evaluation. Credit will be provided to NABP CPE Monitor within 60 days after the activity completion.

2023 Universal Activity Number (UAN): JA0000358-0000-23-025-L01-P; JA0000358-0000-23-025-L01-T

Continuing Education Units

The University of Wisconsin–Madison ICEP, as a member of the University Professional & Continuing Education Association (UPCEA), authorizes this program for 0.1 continuing education units (CEUs) or 1 hour.

Medication Access and Training Expansion Act (MATE)

This session is designed to meet the requirements outlined in the Medication Access and Training Expansion (MATE) Act. ([Click here](#) for more information.) Number of hours : 1

[For this educational activity there are no reported conflicts of interest](#)

▶ Disclosures

- none

Overview

Upon completion of this educational activity members of the healthcare team will be able to:

- ▶ describe the 4-tiered emergency department approach to patients that struggle with opiate use.
- ▶ identify and assess patients that might benefit from MAT in the Emergency Department.
- ▶ demonstrate how to induce a person on buprenorphine in the emergency department.

Who we are



DSM-5 Substance Use Disorder ("Addiction")


- ▶ Tolerance
 - ▶ Withdrawal
- } **Physical Dependence ≠ Use Disorder**
- ▶ Larger amts/longer periods than intended
 - ▶ Persistent desire/failed attempts to quit/control use
 - ▶ Much time obtaining/using/recovering
 - ▶ Important activities sacrificed
 - ▶ Continued use despite known adverse effects
 - ▶ Failure to fulfill major obligations
 - ▶ Recurrent hazardous use
 - ▶ Craving
 - ▶ Ongoing use despite interpersonal problems

2-3 = mild

4-5 = moderate

≥ 6 = severe

HOW CAN WE ADDRESS THE OPIOID EPIDEMIC IN THE ED?



Limiting Opiates from the ED

- ▶ Education that the expectation is to limit the number of opiate prescriptions
- ▶ Single sign on for ePDMP
- ▶ Hard stop for opiate prescriptions

ALTO

Cervical injections

Dental blocks

IV lidocaine protocolized for pain

IV ketamine protocolized for pain

Harm reduction

- ▶ Narcan kits
- ▶ Fentanyl strips

If there is no reaction in 2...

Injectable naloxone

1 Put on gloves, if available. Remove cap from naloxone vial. Uncover the needle.



2 Insert needle through rubber plug with vial upside down. Pull back on plunger and draw up 1 mL of naloxone.



With needle pointing up, push plunger to remove air in syringe (A). Lock needle in place with a quarter turn (B).



3 Insert the needle into the muscle of the upper arm or thigh (see image at right), through clothing if needed. Push on the plunger to inject the naloxone.



Auto-injector (EVZIO®)

1 Pull auto-injector from outer case. Pull off red safety guard.

2 Place the black end of the auto-injector against the outer thigh, through clothing if needed. Press firmly and hold in place for 5 seconds.

- Provided with...
- Instructed on how to...

Signature _____
Trainer's Signature _____

NDC 69547-353-02 0.1 mL intranasal spray per unit
For use in the nose only **Rx Only**

NARCAN® (naloxone HCl)
NASAL SPRAY 4 mg

Use NARCAN® Nasal Spray for known or suspected opioid overdose in adults and children.

Important: For use in the nose only.
Do not remove or test the NARCAN® Nasal Spray until ready to use

This box contains two (2) 4-mg doses of naloxone HCl nasal spray

Two Pack

CHECK PRODUCT EXPIRATION DATE BEFORE USE.

OPEN HERE FOR QUICK START GUIDE
Opioid Overdose Response Instructions

1 Strip / Drug Test

Rapid Response

LOT: [illegible]
Do not reuse
Box of 25 (5.46 x 12.30 cm)
BPN Inc. (United States)
Merrill Lynch (Canada)

Central document(s) document(s)
BPN Inc. (United States)
Merrill Lynch (Canada)

Treatment of OUD and Referral

- ▶ Recovery Coaches
- ▶ MAT (Buprenorphine induction)

Recovery Coaches

- ▶ Began October 2018
- ▶ Initial grant from Voices to Recovery
- ▶ Pilot Program at St. Joseph Hospital
- ▶ Expanded to all Ascension ED's in May 2022


Recovery Coach Role

- ▶ Recovery Coach has lived experience with opiate use
- ▶ They are there to listen and meet the person where they are.
- ▶ Offer support
- ▶ Offer resources
- ▶ Follow up if patient agreeable after discharge
- ▶ Assist with support, navigation, transport, treatment

MAT in the ED

- ▶ Essentially Buprenorphine
- ▶ X-waiver was a major barrier initially
- ▶ Stigma (both patients and providers)
- ▶ Protocols incorporated into EHR

Emergency Department Initiation of Buprenorphine for Opioid Use Disorder



Conclusions

- ▶ Stigma is real.
- ▶ Education is necessary.
- ▶ Prioritizing and revisiting OUD in the ED is essential.
- ▶ Don't reinvent the wheel.

References

- ▶ CA Bridge: retrieved from: <https://cabridge.org/>